Biocept Inc. and Protean BioDiagnostics Inc. are collaborating to research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
Researchers at Indiana University School of Medicine and IU Simon Comprehensive Cancer Center have developed a novel antibody-drug conjugate for treating triple negative breast cancer.
FDA has approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.
Exact Sciences Corp. has entered into an agreement to acquire Ashion Analytics from The Translational Genomics Research Institute, an affiliate of City of Hope.
FDA has granted accelerated approval to Ukoniq (umbralisib), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the following indications:
FDA has approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma
FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma previously treated with an hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics In care collaborating to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents, which target two of the most frequent KRAS mutations in cancer.
The European Commission has granted full marketing authorization to Inrebic (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, who are Janus Associated Kinase inhibitor naïve or have been treated with ruxolitinib.
FDA has granted accelerated approval to Tepmetko (tepotinib) for adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations.
